Lowman W., Aithma N., Coetzee J.F., Dusè A.G., Mer M.
Department of Clinical Microbiology and Infectious Diseases, School of Pathology, University of the Witwatersrand; and Infection Control Services Laboratory, National Health Laboratory Services, Johannesburg, South Africa; Infection Control Services Laboratory, National Health Laboratory Services, South Africa; Department of Anaesthesiology and Critical Care, Stellenbosch University, Tygerberg, W Cape, South Africa; Department of Medicine, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa
Lowman, W., Department of Clinical Microbiology and Infectious Diseases, School of Pathology, University of the Witwatersrand; and Infection Control Services Laboratory, National Health Laboratory Services, Johannesburg, South Africa; Aithma, N., Infection Control Services Laboratory, National Health Laboratory Services, South Africa; Coetzee, J.F., Department of Anaesthesiology and Critical Care, Stellenbosch University, Tygerberg, W Cape, South Africa; Dusè, A.G., Department of Clinical Microbiology and Infectious Diseases, School of Pathology, University of the Witwatersrand; and Infection Control Services Laboratory, National Health Laboratory Services, Johannesburg, South Africa; Mer, M., Department of Medicine, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, South Africa
We evaluated the in vitro microbiological efficacy of a generic ceftriaxone product against several clinically significant organisms collected from sterile sites. The minimum inhibitory concentration (MIC) of each was determined simultaneously with the reference and the generic ceftriaxone product. Comparative analysis of MICs between the two products for each isolate was performed using both categorical (interpretive) agreement and essential (actual MIC value) agreement. A total of 260 isolates were tested. Overall, there was categorical agreement of 98.9% and essential agreement of 95.8%. The categorical agreement for all isolates (96.7 - 100%) accorded with international standards, as no very major errors were seen and the major error rate was less than 3%. Of the 90 isolates of E. coli (40), Klebsiella spp. (40) and Salmonella spp. (10), 87.6% had an MIC less than or equal to 0.12 mg/l. The generic ceftriaxone product showed equivalent efficacy by MIC determination to the reference formulation. Ceftriaxone remains a viable and useful antimicrobial agent against a variety of clinically relevant organisms in our setting.
ceftriaxone; extended spectrum beta lactamase; alpha hemolytic Streptococcus; antibiotic sensitivity; article; bacterium isolate; broth dilution; comparative study; drug efficacy; Enterobacteriaceae; Escherichia coli; Haemophilus influenzae; Klebsiella; minimum inhibitory concentration; nonhuman; phenotype; Salmonella; South Africa; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; Anti-Bacterial Agents; Bacteria; Ceftriaxone; Citrobacter; Drug Resistance, Bacterial; Escherichia coli; Haemophilus influenzae; Humans; Klebsiella; Microbial Sensitivity Tests; Reproducibility of Results; Staphylococcus aureus; Viridans Streptococci